Nimbus Therapeutics, a clinical-stage company that designs and develops breakthrough medicines, announced the closing of Takeda’s (TSE: 4502/NYSE:TAK) acquisition of its wholly-owned subsidiary, Nimbus Lakshmi, Inc. and its TYK2 inhibitor program. This comes with an impressive payout of $4 billion upfront to Nimbus, as well as up to $2 billion in additional sales-based milestone payments. The TYK2 inhibitor, NDI-034858, is now known as TAK-279 and is expected to make a major impact in the medical world.
We are delighted to have achieved a major milestone with the development of a preeminent oral, selective allosteric TYK2 inhibitor. This breakthrough molecule has the potential to make a big difference in the lives of patients with a wide range of immune-mediated diseases. At Nimbus, we strive to create innovative medicines at the intersection of computational chemistry and pharmaceutical sciences, and this success is yet another testament to our commitment to our mission.
At an upcoming medical meeting, Nimbus will present the results of their Phase 2b clinical trial of NDI-034858, a promising treatment for moderate-to-severe plaque psoriasis. The trial achieved its primary efficacy endpoint, with a statistically significant greater proportion of patients reaching PASI-75 (a 75% improvement in skin lesions as measured by the Psoriasis Area and Severity Index) compared to the placebo after 12 weeks. This is a major breakthrough in the field of psoriasis treatment, with the potential to drastically improve patients’ quality of life.
Nimbus is revolutionizing the treatment of cancer, autoimmune diseases and metabolic disorders with NDI-101150, a potent HPK1 inhibitor, currently being tested in a Phase 1/2 clinical trial in people with solid tumors. This innovative approach is set to significantly improve the outlook for those living with these life-threatening conditions.
About Nimbus Therapeutics
Nimbus Therapeutics is revolutionizing the way we discover and develop medicines. By utilizing leading-edge computational technologies and machine learning-based predictive modeling approaches, they are developing novel small molecule medicines to address difficult-to-drug targets implicated in multiple human diseases. With a clinical-stage program, HPK1 (NCT05128487) and a diverse portfolio of preclinical programs focused on cancer, inflammatory and autoimmune conditions and metabolic diseases, Nimbus is on the cutting edge of drug discovery and development. Located in Boston, MA, Nimbus is paving the way for more effective and innovative therapeutics.